10–25% of the tumour cells contained prolactin and it is possible that the patient's impotence was due to hyperprolactinaemia. The combination of apparently benign histological features followed by seeding through the CSF after 13 years has been described recently. The tumour tissue deposits occurred in sites at which the radiotherapy dose was low or to which radiotherapy was not given. This suggests that a pituitary adenoma with potential to metastasise may respond to radiotherapy. Dissemination of tumour during surgery cannot be excluded as a cause of arachnoid seeding but such seeding has been observed in patients who have not previously had operation.

We conclude that the surgeon as well as the pathologist should be aware that "ectopic" suprasellar adenohipophyseal cells and adenomas occur in the supra- and parasellar region. The diagnosis can be made by the application of immunohistochemistry and electronmicroscopy to biopsy material. This tumour may be hormonally active so that endocrinological studies should be performed before operation.

W KAMPHORST
Department of Neuropathology
JG WOLBERS
H PONSSER
Department of Neurosurgery
ABMF KARIM
Department of Radiotherapy,
Fris University Hospital,
P O Box 7057;
1007 MB Amsterdam,
The Netherlands

Correspondence to: Dr Michael Weller.


5 Prei K, Siegl C, Goursatger P, Bodmer S, Schwerdel G, Fontana A. Antigen presentation and tumor cytotoxicity by interferon- 

Tumour necrosis factor-α in malignant melanomatous meningitis

Meningeal infiltration by neoplastic cells is an ominous prognostic sign in patients suffering from systemic cancer. After carcinoma of the breast and bronchus, malignant melanoma is the third most common primary tumour in patients with diffuse leptomeningeval metastasis.1 Intraintricial synthesis of IgG and detection of oligoclonal immunoglobulin bands on isoelectric focusing gels of CSF in meningeval carcinomatosis, suggest immune recognition of tumour cells within the CNS.2 We determined the levels of two cytokines, tumour necrosis factor-α (TNFa) and interferon gamma (IFNy), in paired serum and CSF samples obtained from 45 patients with meningeval malignancies. Cytokines, for example, interleukins, interferons, and TNFα, are multifunctional messenger molecules currently evaluated for new approaches of immunotherapy in disseminated malignancies. Our study included CSF and serum samples, stored at −70°C after lumbar puncture and centrifugation without further processing, from patients with diffuse leptomeningeval metastasis from cancer of the breast (14), bronchus (7), ovary, cervix, prostate, kidney, stomach (1 each), and unknown origin (4), malignant melanoma (4), non-Hodgkin lymphoma (9), multiple myeloma (1), and Hodgkin's disease (1). Commercial ELISA kits were purchased from British Biotechnology, Oxford, UK, (TNFa), and Endogen, Boston, USA (IFNy). Sensitivity was 50 ng/l for IFNy and 40 ng/l for TNFa. IFNy was found in the CSF in carcinomatosis from two cases of breast cancer (322 and 899 ng/l), one case of cancer of unknown origin (639 ng/l), and one case of non-Hodgkin lymphoma (66 ng/l). IFNy in serum was positive in two cases of cancer of the breast (56 and 901 ng/l) neither of which had detectable IFNy in the CSF, and one case of cancer of the bronchus (326 ng/l). IFNy was also present in the serum of the patient with non-Hodgkin lymphoma (48 ng/l) who had IFNy in the CSF.

TNFαs was detected in three of four CSF samples but not in the serum of patients with meningeval infiltration from melanoma (61, 78, and 166 ng/l) or in CSF other neoplastic diseases. TNFα was, however, detected in sera from three patients with meningeval carcinomatosis (breast, 534 ng/l; bronchus, 46 ng/l); unknown origin, 118 ng/l) and one patient with non-Hodgkin lymphoma (48 ng/l). None of the CSF or serum samples contained both IFNy and TNFα.

TNFαs may mediate inflammatory tissue destruction in bacterial meningitis, particularly severe meningococcal disease, inflammatory demyelination, and tumour cell cytotoxicity in vitro.

To our knowledge, this is the first report on TNFαs in meningeval malignancies. New approaches to an immunotherapy of malignant melanoma are evolving rapidly, and are based on specific immunogenetic features of this malignancy, for example, inhibition of tumour cell proliferation in vitro by IFNy and TNFαs. Although elevated levels of TNFαs in the CSF of patients with malignant melanomatous meningitis are still a preliminary finding, the lack of similar results in a large control group of other meningeval malignancies confirms the existence of special interactions between melanoma cells and the host's immune system. This warrants further investigation.
Tumour necrosis factor-alpha in malignant melanomatous meningitis.

M Weller, A Stevens, N Sommer and H Wiethölter

*J Neurol Neurosurg Psychiatry* 1992 55: 74
doi: 10.1136/jnnp.55.1.74

Updated information and services can be found at:
http://jnnp.bmj.com/content/55/1/74.1.citation

**Email alerting service**

*These include:*

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/